The global combination vaccines market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).
Combination vaccines are a mixture of two or more vaccines that can be administered individually into a single vaccine shot. This allows individuals to get fewer shots to get benefited from more number of diseases, easing the process for both the patients and the administrators with the administration of a single shot. Therefore, the human combination vaccines market has an advantage over individual vaccines.
The global combination vaccines market growth is driven by the increase in the prevalence of infectious diseases, the rise in the paediatric population and the rising interest of manufacturers in developing novel vaccines to target a wide range of diseases.
An increase in the prevalence of infectious diseases coupled with the rising interest of manufacturers in developing novel vaccines is expected to hold the largest share in this market segment
Since infants do not have a fully developed immune system at early stages of life, they are more vulnerable to many infectious diseases. For instance, the Centers for Disease Control and Prevention (CDC) reported that approximately 3.1% of children population in the age group 5-11 years was in fair or poor health in the U.S in 2019. This further leads to an increase in the demand for combination vaccines thus, driving the market. Also, an increase in antiviral drug resistance has shifted the market trend towards combination vaccines as these vaccines eliminate the problem of drug resistance. For instance, according to a review article published in Nature, a scientific journal in 2021, use of vaccines reduces the spread of antimicrobial drug resistance as they are used specifically for a given infectious antigen.
Moreover, rising interest of manufacturers in developing novel vaccines to target a wide range of diseases boost the growth potential of human combination vaccine market. For instance, in September 2020, Sanofi Pasteur, launched Tetraxim (DTaP-IPV) as the first full-dose DTaP booster vaccine for children that provides protection against four infectious diseases- Diptheria, Tetanus, Whooping cough, and Polio.
Download Sample Brochure @ https://www.datamintelligence.com/download-sample/combination-vaccines-market
By Product Type
- Inactivated vaccine
- Live attenuated vaccine
By Age Group
By Combination Type
- DTaP/IPV/Hep B
- MMR II
- Hep B-Hib
The global combination vaccines market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Sanofi, Cadila Healthcare Ltd., GlaxoSmithKline plc, CSL Ltd., Mitsubishi Tanabe Pharma Corp., DAIICHI SANKYO COMPANY, LIMITED, Merck & Co., Crunchbase Inc., Mass Biologics, Astrazeneca.
DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision-making in designing disruptive solutions.